Antibodies against thyroid-stimulating hormone receptor cause maternal-neonatal transmission of Graves' Disease

xlomafota13 shared this article with you from Inoreader Antibodies against thyroid-stimulating hormone receptor cause maternal-neonatal transmission of Graves' Disease Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1253. doi: 10.3892/etm.2021.10688. Epub 2021 Sep 3. ABSTRACT The present study aimed to investigate whether the thyroid-stimulating hormone receptor (TSHR) autoantibodies (Ab) from mothers with Graves' disease (GD) could cause neonatal thyroid disease and the underlying mechanisms of this. An adenovirus expressing the TSHR A-subunit and a control adenovirus expressing β-galactosidase was constructed by Beijing Sino Geno Max Co., Ltd. The sequences were subsequently verified and amplified via PCR. A GD model was established in female BALB/c mice (n=90) by three intramuscular injections of a TSHR-expressing adenovirus (Ad-TSHR). Mice injected with Ad-β-galactosidase served as a sham immunization group. The immunized females were paired with unimmunized males to generate offspring. The serum levels of TSHR-Ab and thyroxine (T4) of mothers and neonates were measured after delivery. Breast milk was collected f rom the stomachs of neonatal mice to determine the TSHR-Ab levels. The positive rate of serum TSHR-Ab (>0.3 IU/l) in the TSHR group was 99% (89/90) and 0% in the sham group. The mother mice in the TSHR group had elevated serum T4 levels and the thyroid pathological features of Graves' hyperthyroidism.GD mice gave birth to smaller newborns with thyroid pathological changes and higher serum levels of TSHR-Ab and T4, compared to the offspring in the sham group. The TSHR-Ab levels in breast milk from the GD mice declined with time. Mice immunized with Ad-TSHR exhibited the clinicopathological features of human GD and give birth to neonates with thyroid disease at birth. PMID:34603521 | PMC:PMC8453324 | DOI:10.3892/etm.2021.10688 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma

xlomafota13 shared this article with you from Inoreader MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1257. doi: 10.3892/etm.2021.10692. Epub 2021 Sep 3. ABSTRACT [This retracts the article DOI: 10.3892/etm.2017.5245.]. PMID:34603525 | PMC:PMC8453323 | DOI:10.3892/etm.2021.10692 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

The added value of three-dimensional ultrasonography in uterine pathology

xlomafota13 shared this article with you from Inoreader The added value of three-dimensional ultrasonography in uterine pathology Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1261. doi: 10.3892/etm.2021.10696. Epub 2021 Sep 6. ABSTRACT The rapid development achieved over the last decades in volume rendering of ultrasound data, known as three-dimensional (3D) ultrasound technique, leads to new opportunities for refining the diagnosis in many gynaecologic conditions. The aim of the present study was to evaluate the advantages of 3D ultrasound over two-dimensional (2D) ultrasound in uterine pathology and to establish the optimal time point during the menstrual cycle to perform 3D ultrasound examination in order to achieve the maximum of useful information. A cross-sectional study on 200 patients who underwent gynaecologic 2D and 3D ultrasound examinations was performed. The addition of 3D examination to 2D ultrasound in uterine pathology provided the most useful information concerning: Congenital uterine anomalies, intrauterine devices (IUDs), adenomyosis, and submucous myomas. The findings showed that the 3D ultrasound scan is a useful tool in gynaecology, especially in cases with congenital uterine anomalies, myoma, and IUD. Although initially it was used for research purposes only, recent findings suggest its usefulness in routine ultrasound scan and the possibility of witnessing its introduction as a recommended examination procedure in the foreseeable future. Further research should be conducted in order to establish the sensitivity of 3D ultrasound in the detection of minor endometrial conditions, by correlating the imaging findings with the hysteroscopic results. PMID:34603529 | PMC:PMC8453339 | DOI:10.3892/etm.2021.10696 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review)

xlomafota13 shared this article with you from Inoreader Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1263. doi: 10.3892/etm.2021.10698. Epub 2021 Sep 6. ABSTRACT Asthma is a variable chronic respiratory disease characterized by airway inflammation and hyperresponsiveness, bronchoconstriction, and mucus hypersecretion. While most patients with asthma achieve good control of the disease, 5-10% experience severe symptoms and recurrent exacerbation despite the maximal offered therapy with inhaled corticosteroids and long acting bronchodilators. In previous years, novel biological therapies have become available, and various asthma phenotypes that are characterized by specific biomarkers have been identified. Currently approved biological agents target inflammatory molecules of the type 2 inflammatory pathway, and are effective at decreasing the frequency of asthma attacks, controlling symptoms and decreasing use of systemic steroids. The present study reviewed the effectiveness and safety profile of the curren tly approved biological drugs and provided an overview of the assessment of patients with severe asthma who are potentially suitable for biological therapy, in order to help clinicians to select the most appropriate biological agent. PMID:34603531 | PMC:PMC8453334 | DOI:10.3892/etm.2021.10698 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Falx Cerebelli Meningioma: Case Report of a Rarely Occurring Tumor, Management Nuances, and Literature Review

xlomafota13 shared this article with you from Inoreader Falx Cerebelli Meningioma: Case Report of a Rarely Occurring Tumor, Management Nuances, and Literature Review Via leak of cerebrospinal fluid J Neurol Surg Rep. 2021 Sep 29;82(3):e32-e35. doi: 10.1055/s-0041-1735905. eCollection 2021 Jul. ABSTRACT The falx cerebelli is a small crescent fold of dura mater that is attached to the internal occipital crest and projects forward into the posterior cerebellar notch between the cerebellar hemispheres. We report a rare case of a 61-year-old female who presented with a 1-month history of headache and gait instability. Imaging findings were suggestive of a meningioma arising from the falx cerebelli. Complete surgical resection was achieved with a standard posterior fossa midline approach. Duraplasty was performed using animal allograft dura (Duraguard) and additional layers of oxidized cellulose preparation (Surgicel), fibrin sealant, and nonsuturable collagen matrix (Duragen) were utilized to reduce the risk of a cerebrospinal fluid leak. Pathology confirmed a World Health Organization (WHO) grade-I meningioma. Postoperatively, patient with asymptomatic thrombosis of the left transverse/sigmoid sinuses and later with a pseudomeningocele managed with a lumbar drain. To our knowledge, this is the second documented case in the literature. We discuss intraoperative nuances and unique aspects in the postoperative care and management of these patients. PMID:34603931 | PMC:PMC8481004 | DOI:10.1055/s-0041-17359 05 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Vocal Cord Hemangioma: A Common Tumor in an Unusual Localization. A Case Report with Short Review of Literature

xlomafota13 shared this article with you from Inoreader Vocal Cord Hemangioma: A Common Tumor in an Unusual Localization. A Case Report with Short Review of Literature Via Otolaryngology Indian Abstract Laryngeal adult-type hemangiomas are very rare lesions, more frequent in men, whose optimal treatment consists of microlaryngoscopical excision. We herein report a case of larynx cavernous hemangioma in a 64-year-old woman with hoarseness for about six months. Histologically, the tumor was composed of multiple vessels embedded in an edematous stroma. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Needle Fracture During Injection Medialization Laryngoplasty

xlomafota13 shared this article with you from Inoreader Needle Fracture During Injection Medialization Laryngoplasty Via Journal of Voice Awake injection medialization laryngoplasty is one of the most common therapeutic procedures done by laryngologists in the office or at the bedside. Complications of injection needle fracture are rarely reported. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy

xlomafota13 shared this article with you from Inoreader Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy Via leak of cerebrospinal fluid Muscle Nerve. 2021 Oct 4. doi: 10.1002/mus.27425. Online ahead of print. ABSTRACT INTRODUCTION/AIMS: Intrathecal administration of nusinersen is challenging in patients with spinal muscular atrophy (SMA) who have spine deformities or fusions. We prospectively studied the safety and efficacy of nusinersen administration via an indwelling subcutaneous intrathecal catheter (SIC) for SMA patients with advanced disease. METHODS: Seventeen participants commenced nusinersen therapy between 2.7 and 31.5 years of age and received 9-12 doses via SIC. Safety was assessed in all participants. A separate efficacy analysis comprised 11 non-ambulatory, treatment-naïve SMA patients (18.1 ± 6.8 years) with three SMN2 copies and complex spine anatomy. RESULTS: In the safety analysis, 14 treatment-related adverse events (AEs) occurred among 12 (71%) participants; all were related to the SIC and not nusinersen. Device-related AEs interfered with 2. 5% of nusinersen doses. Four SICs (24%) required surgical revision due to mechanical malfunction with or without cerebrospinal fluid leak (n = 2), and one (6%) was removed due to Staphylococcus epidermidis meningitis. In the efficacy analysis, mean performance on the Nine Hole Peg Test improved in dominant (15.9%, p = 0.0.012) and non-dominant (19.0%, p = 0.008) hands and grip strength increased 44.9% (p = 0.0.031). We observed no significant changes in motor scales, muscle force, pulmonary function, or SMA biomarkers. All participants in the efficacy cohort reported one or more subjective improvements of endurance, purposeful hand use, arm strength, head control, and/or speech. DISCUSSION: For SMA patients with complex spine anatomy, the SIC allows for reliable outpatient administration of nusinersen that results in meaningful improvements of upper limb function, but introduces risks of technical malfunction and iatrogenic infection. This article is protected by copyright. Al l rights reserved. PMID:34606118 | DOI:10.1002/mus.27425 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Mini-Incision Parotidectomy-Our Technique

xlomafota13 shared this article with you from Inoreader Mini-Incision Parotidectomy-Our Technique Via Otolaryngology Indian Abstract Traditional parotidectomy incision was devised by Blair (1912) which was modified by Bailey (1941). Over the years various approaches and techniques have evolved to improve the aesthetic outcome and at the same time for complete disease clearance with reduced complications. In this study, we evaluated the feasibility of our mini-incision parotidectomy technique along with the surgical and quality of life (QOL) outcomes. This prospective case series was conducted at Apollo Hospitals, Bangalore over a period of 2 years (June 2018-August 2020) and includes 20 patients. The surgical outcomes were assessed in terms of feasibility of mini-incision technique with respect to levels of parotid involved and functional outcomes in terms of presence or absence of complications like facial palsy (temporary or permanent), seroma and Frey's syndrome. Patient related quality of life (QOL) outcomes were assessed in terms of post-operative pain score, patient comfort score and cosmetic score by using numerical rating scale-11 (NRS-11). The mini-incision parotidectomy technique is feasible for lesions in all the parotid levels and conversion or lengthening of incision was not needed in any of the cases. 2(10%) patients had temporary facial palsy (House-Brackman grade III) which was recovered within 3 weeks after surgery. One patient (5%) with adenoid cystic carcinoma had permanent facial palsy. Out of 20 patients 2(10%) had seroma and 1(5%) patient presented with Frey's syndrome. Mean post-operative pain score at 0, 6 and 24 h were 4.8, 3.4 and 1.8 out of 10 respectively. Mean comfort score was 9 out of 10 and mean cosmetic score was 9.5 out of 10. Mini-incision parotidectomy technique can render improved functional as well as aesthetic outcomes after parotidectomy without compromising the surgical clearance of the disease process. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A New Biomarker in Differentiation of Mucosal Chronic Otitis Media from Squamous Chronic Otitis Media: The Systemic Immune-Inflammation Index (SII)

xlomafota13 shared this article with you from Inoreader A New Biomarker in Differentiation of Mucosal Chronic Otitis Media from Squamous Chronic Otitis Media: The Systemic Immune-Inflammation Index (SII) Via Otolaryngology Indian Abstract The Systemic Immune-inflammation Index (SII) is a new biomarker based on the number of neutrophils, platelets, and lymphocytes in the Complete blood count, and is shown as diagnostic and prognostic in many diseases. Mucosal or Squamous COM differentiation is necessary preoperatively in chronic otitis media patients. The purpose of this study was to test the predictive value of inflammation markers to predict the differentiation of Mucosal COM and Squamous COM. Our aim is; using "SII" as a powerful test to differentiate cholesteatoma and active mucosal middle ear disease. In the present study, 300 patients who underwent mastoidectomy ± tympanoplasty between 2010 and 2020 were retrospectively evaluated. The patients were divided into two equal groups as clinical, microscopically, and pathologically Squamosal COM (Cholesteatoma) and Mucosal COM (Suppurative) (n = 150). Routine hemogram tests were performed for both groups. White blood cell, red blood cell, neutrophil, lymphocyte, and platelet numbers were calculated. The SII value was calculated manually according to the formula of "neutrophil × platelet/lymphocyte. There were a total of 300 patients who were aged 20–63 in both groups. A total of 130 of these patients were male (43%), and 170 (57%) were female. In terms of NLR and PLR, Group 2 (Mucosal COM) had higher values at statistically significant levels (p < 0.001, p < 0.001, respectively). In terms of SII, Group 2 (Mucosal COM) had higher values at statistically significant levels (p < 0.001). According to the results of the ROC Analysis in our series, it was found that NLR, PLR, and SII values were above the acceptable level, and were statistically significant (p < 0.001, p < 0.001, p < 0.001, respectively). The cut-off value of SII was 470.29, sensitivity was 65.8, and specificity was 34. According to our study, hig h SII values in COM differentiation are very important in diagnosing Mucosal COM. SII values can help to the diagnosis in Squamous COM/Mucosal COM differentiation. There is no current practical, inexpensive, and widespread laboratory test used in the Mucosal/Squamous COM differentiation. SII can be diagnostic, and determine the treatment in this differentiation. A great number of studies are needed for SII values to become standard in COM. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network

xlomafota13 shared this article with you from Inoreader Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network Via Association française pour l'étude du cancer Bull Cancer. 2021 Sep 27:S0007-4551(21)00303-9. doi: 10.1016/j.bulcan.2021.06.009. Online ahead of print. ABSTRACT Refractory thyroid cancers include radio-iodine-refractory cancers, metastatic or locally advanced unresectable medullary and anaplastic thyroid cancers. Their management has been based for several years on the use of multi-target kinase inhibitors, with anti-angiogenic action, with the exception of anaplastic cancers usually treated with chemo- and radiotherapy. The situation has recently evolved due to the availability of molecular genotyping techniques allowing the discovery of rare but targetable molecular abnormalities. New treatment options have become available, more effective and less toxic than the previously available multi-target kinase inhibitors. The management of refractory thyroid cancers is therefore becoming more complex both at a diagnosis level with the need to know when, how and why to look for these mo lecular abnormalities but also at a therapeutic level, innovative treatments being hardly accessible. The cost of molecular analyzes and the access to treatments need also to be homogenized because disparities could lead to inequality of care at a national or international level. Finally, the strategy of identifying molecular alterations and treating these rare tumors reinforces the importance of a discussion in a multidisciplinary consultation meeting. PMID:34593218 | DOI:10.1016/j.bulcan.2021.06.009 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Treatment of burn contractures with allogeneic human dermal fibroblasts improves Vancouver scar scale: A phase I/II trial

xlomafota13 shared this article with you from Inoreader Treatment of burn contractures with allogeneic human dermal fibroblasts improves Vancouver scar scale: A phase I/II trial Via Journal of plastic, reconstructive & aesthetic surgery : JPRAS J Plast Reconstr Aesthet Surg. 2021 Sep 17:S1748-6815(21)00405-8. doi: 10.1016/j.bjps.2021.08.018. Online ahead of print. NO ABSTRACT PMID:34593339 | DOI:10.1016/j.bjps.2021.08.018 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.